✦ LIBER ✦

P-488 Phase II randomized trial of single-agent pemetrexed orsequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy

✍ Scribed by Gridelli, C.; Reck, M.; Gregorc, V.; Migliorino, M.; Muller, T.; Manegold, C.; Favaretto, A.; Schmittel, A.; Caffo, O.; Blatter, J.; Munoz, M.; Crucitta, E.; Rossi, A.; Koschel, G.

Book ID: 118573393
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 140 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(05)80981-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Motexafin Gadolinium (MGd) is Active as

Motexafin Gadolinium (MGd) is Active as a Single Agent and in Combination with Pemetrexed and Docetaxel in Advanced Non–Small-Cell Lung Cancer (NSCLC) Patients who Failed Platinum-Based Chemotherapy: Early Results of 3 Phase II Trials

✍ R.B. Natale; G. Nicholas; K. Pandya; M. Edelman; S.C. Phan; M.F. Renschler 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 443 KB

A randomized phase II trial evaluating s

A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

✍ Cappuzzo, F.; Novello, S.; De Marinis, F.; Selvaggi, G.; Scagliotti, G.V.; Barbi 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 167 KB